INVO Stock Skyrockets On Amended Deal With Swiss Pharma Firm

2 min read | March 10, 2021 07:51 AM EST | By Anuj

Google News:

INVO Stock Skyrockets On Amended Deal With Swiss Pharma Firm

Details of INVO’s Amended Agreement

The various clauses of the INVO’S amended agreement with Ferring Pharmaceuticals are as follows:

The new agreement allows INVO to expand company-owned clinics in the United States and eliminates earlier imposed geographical restrictions.
Under the new agreement, Ferring Pharmaceuticals will place the remaining minimum contractual purchase order worth $501,000.
CEO of INVO Bioscience, Steve Shum expressed optimism in the partnership with Ferring Pharmaceuticals and the use of INVOcell in the expanded U.S. geography under the new commercialization agreement.

According to Steve Shum, this strategy has a three-fold impact:

It will help increase industry capacity,
Ensure affordability for patients and
Facilitate greater access for patients.

(Source: Kalkine Media)

INVO claims the patented INVOcell device is used as an incubator and is ideal for early embryo development through in vivo conception and scores over traditional procedures like IVF where embryo development happens in a laboratory incubator.

With this novel procedure, INVOcell also seeks to lower the cost and increase the accessibility of the treatment.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.